Dr. Richard J. Solomon, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (1970)
- Years since graduation
- 56
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 94
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1970Medical school: Yale University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Nephrology Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Univ. of Vermont - Fletcher Allen Health Care Burlington, VT
- The University of Vermont Health Network - Champl Plattsburgh, NY
- Central Vermont Medical Center Barre, VT
- Northwestern Medical Center Inc Saint Albans, VT
- Porter Hospital Inc Middlebury, VT
Medical groups
- University of Vermont Medical Center Inc (1,208 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 94
- Services billed
- 121
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| New patient office or other outpatient visit, 45-59 minutes | 39 | 39 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 29 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 20 | 14 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Burlington, VT | 49 |
| Torsemide Other prescribers in Burlington, VT | 21 |
| Furosemide Other prescribers in Burlington, VT | 15 |
| Amlodipine Besylate Other prescribers in Burlington, VT | 13 |
| Mycophenolate Mofetil Other prescribers in Burlington, VT | 12 |
| Jardiance (empagliflozin) Other prescribers in Burlington, VT | 11 |
| Famotidine Other prescribers in Burlington, VT | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $212,937 in research payments for these studies, mostly to the institutions running them.
- A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - A Study to Determine the Prevalence, Demographic, and Clinical Characteristics Associated With PKD1 Variant Groups in Individuals Diagnosed With ADPKD
Vertex Pharmaceuticals Incorporated - A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
AstraZeneca Pharmaceuticals LP - A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.